Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2020-01, Vol.125, p.83-93
Main Authors: Latenstein, Anouk E.J., van der Geest, Lydia G.M., Bonsing, Bert A., Groot Koerkamp, Bas, Haj Mohammad, Nadia, de Hingh, Ignace H.J.T., de Meijer, Vincent E., Molenaar, Izaak Q., van Santvoort, Hjalmar C., van Tienhoven, Geertjan, Verheij, Joanne, Vissers, Pauline A.J., de Vos-Geelen, Judith, Busch, Olivier R., van Eijck, Casper H.J., van Laarhoven, Hanneke W.M., Besselink, Marc G., Wilmink, Johanna W.
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adenocarcinoma
Chemotherapy
Epidemiology
Incidence
Irinotecan
Metastases
Oxaliplatin
Pancreas
Pancreatic cancer
Population studies
Survival
Survival analysis
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC. Patients with PDAC (1997–2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997–2000, 2001–2004, 2005–2008, 2009–2012 and 2013–2016). Kaplan–Meier survival analysis was used to calculate overall survival. In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997–2000) to 15.3 (2013–2016) per 100,000 (p 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2019.11.002